Title

The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers

on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A

meta-analysis

Authors: Ghosal S¹, Mukherjee Jagat J², Sinha B³, Gangopadhyay K⁴

1. Consultant endocrinologist, Nightingale Hospital, Kolkata, India.

2. Consultant endocrinologist, Apollo Gleneagles Hospital, Kolkata, India.

3. Consultant endocrinologist, AMRI Hospitals, Kolkata, India.

4. Consultant endocrinologist, Fortis & Peerless Hospital, Kolkata, India.

Corresponding author:

Samit Ghosal. Email: ramdasghosal@gmail.com. Mobile: 9674328281.

Keywords: Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker,

Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronovairus-2

(SARS-CoV2), hypertension, death

Summary

Background: Effect of angiotensin converting enzyme inhibitors (ACEi) and angiotensin

receptor blockers (ARB) on outcomes in patients with coronavirus disease 2019 (COVID-19)

is uncertain. Available evidence is limited to a few retrospective observational studies with

small number of patients.

Methods: We did a meta-analysis to assess the effect of ACEi/ARB in patients with COVID-19

on severity of disease, risk for hospitalisation, and death compared to those not on

ACEi/ARB. We searched the Cochrane library, PubMed, Embase, ClinicalTrial.gov and

medRxiv for studies published until 21.04.2020. Inclusion criteria included all studies with

patients with confirmed COVID-19 either taking, or not taking, ACEi/ARB. Depending on

degree of heterogeneity, fixed or random effect model was selected to calculate effect size

(Odds ratio).

Findings: Five studies were eligible for meta-analysis. These included 308 patients on

ACEi/ARB, and 1172 not on ACEi/ARB. Compared to patients with COVID-19 not on

ACEi/ARB, there was a statistically significant 44% reduction in odds of developing severe

disease (OR: 0.56; 95% CI: 0.34-1.89, I²=68.15), and 62% reduction in odds of death (OR:

0.38; 95% CI: 0.19-0.74, $I^2=0.000$) in those on ACEi/ARB. There was a non-significant 19%

(OR 0.81; 95% CI: 0.42-1.55, I²: 0.000) reduction in odds of hospitalisation among those on

ACEi/ARB.

Interpretation: It is safe to use ACEi/ARB in patients with COVID-19 requiring these

medications for associated comorbidities. Although limited by confounding factors typical of

a meta-analysis of retrospective observational studies, our data suggests that use of these

medications may reduce risk of developing severe disease and death.

Funding Source: None

Introduction

Coronavirus disease 2019 (COVID-19) is a rapidly unravelling pandemic infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). It is highly infectious, with a case fatality rate of 1% to 5% (1). Despite a wide variability in the prevalence and case fatality rates in the published case-series of COVID-19 from China and USA, it is now clear that patients with underlying pulmonary disease, cardiac disease, hypertension, diabetes mellitus (DM), and renal disease are not only more likely to contract SARS-CoV2 but also have higher morbidity and mortality rates (2, 3, 4). Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are commonly used in patients with cardiac diseases, hypertension, many renal conditions, and DM, which directed attention towards the role of ACEi/ARBs in COVID-19, more so because SARS-CoV2 uses angiotensin-converting enzyme 2 (ACE2) as a co-receptor to enter cells (5).

ACE2, a homologue of angiotensin-converting enzyme 1 (ACE1), cleaves angiotensin II (Ang II), the main active peptide of the renin-angiotensin-aldosterone system (RAAS), to form angiotensin-(1-7) (6, 7). Angiotensin-(1-7) acts as a counter-regulatory peptide by attenuating the deleterious effects of angiotensin II, namely vasoconstriction, sodium retention and fibrosis. ACE2 is a transmembrane protein that is anchored to the apical surface of the cell. It can be cleaved and released into the circulation. ACE2 is expressed in the heart (cardiomyocytes, cardiac fibroblasts, coronary endothelial cells), kidney, testis, gastrointestinal system and type II alveolar cells in the lung (8).

Some, but not all, animal studies have shown that ACEi/ARBs upregulate ACE2 expression (9). This has led to the speculation that use of ACEi/ARB shall not only increase the risk but also the severity of SARS-CoV2 infection. However, unlike in animal models, in the few available human studies, the effects of RAAS inhibitors on ACE2 is far from clear (10,

11). Moreover, animal, and some human, studies have failed to establish the effects of ACEi or ARB on the expression of ACE2 in alveolar cells in the lung.

In contrast to the speculative detrimental effect of upregulation of ACE2 expression in COVID-19, elevated ACE2 levels has a number of beneficial effects. The conversion of Ang II to Ang-(1-7) ameliorates the harmful effects of Ang II, and instead mediates vasodilation and anti-inflammatory effects. Animal studies have suggested that downregulation of ACE2 may result in unopposed action of angiotensin II, that can mediate acute lung injury in viral infections (12), including SARS-CoV2 (13), which can be ameliorated by recombinant ACE2 (14) or RAAS blockade (15). Moreover, animal studies have demonstrated the protective effect of ACE2 on the myocardium (16).

This postulated dual role of ACEi/ARBs, based mostly on theoretical concerns and animal data, has created a dilemma for clinicians because many patients with co-morbidities like diabetes, hypertension, coronary artery disease and chronic kidney disease that increase susceptibility to, and a poor outcome in, SARS-Cov-2 infection, are on ACEi and ARBs. More evidence from the laboratory, and the clinics, are urgently needed to guide frontline physicians during this rapidly progressive pandemic with potential to cause massive devastation. Among these, retrospective analyses of outcomes in patients with COVID-19 who were on ACEi/ARBs can serve as a good evidence base. However, such analyses are limited at present due to very few retrospective case studies with outcomes in patients with SARS-CoV2 infection on ACEi/ARBs (17, 18, 19, 20, 21); moreover, the number of patients included, and the number of outcomes of interest, are small in these individual studies to draw any meaningful conclusions. We therefore did a meta-analysis of the studies reported till 21.04.2020 on the outcomes in patients with COVID-19 on ACEi/ARBs to

strengthen the evidence base by determining the benefit-risk ratio of these medications in patients with COVID-19.

2.0 Materials and methods:

An electronic database search was conducted using the Cochrane library, PubMed, Embase, CT.gov and mdRxiv. Search keywords included "angiotensin receptor blockers", "angiotensin converting enzyme inhibitors", "ACE inhibitors", "ARB", "SARS", "severe acute respiratory syndrome", "COVID-19", "SARS-CoV-2", "mortality", "death", "complications", "acute respiratory distress syndrome", "mortality", "death". The search was conducted irrespective of any language barrier or time constraints. As a part of advanced screening references of identified citations were also screened for any additional information missed out in the screening process. [Figure 1]




Figure 1: Study selection process. ACEi: Angiotensin converting enzyme inhibitors, ARB= Angiotensin receptor blockers.

2.1 Inclusion criteria

A broad web-based search was conducted to identify all citations published, or in the preprint stage. Having narrowed down the search tailored to the aims of our study, we finalised the citations to be included as part of the meta-analysis by incorporating a predefined set of inclusion criteria. 1. The studies must report a clear distinction between use and non-use of ACEi/ARB as the two-comparator arms. If the studies provided data separately for ACEi or ARB then we intended to analyse the impact on outcomes independently. However, in the absence of non-segregation of data between ACEi or ARB, analysis will be performed for the combined use of ACEi and ARB.

- 2. Studies must include patients with SARS-CoV-2 infections only.
- 3. Severity of infection, death and hospitalisation was the primary outcomes of interest.
- 4. In the process of data analysis any additional outcome of importance could be included after arriving at a consensus.
- 5. All patients in the active-treatment arm must have been treated with ACEi/ARB.

We excluded all data presented in the form of commentaries, review articles, or case reports. Any data unrelated to SARS-CoV-2 infection were also excluded.

2.2 Process of study selection

The study was conceptualised by JJM. The article screening process was performed in a cyclical manner to make the process more robust. In phase one SG and BS conducted the web search jointly with mutual consultations. Any dispute was resolved on the basis of a mutually acceptable consensus. The inclusion and exclusion criteria were devised by JJM & KKG. Once the whole study selection process was completed, the team performed the same search in reverse order, with JJM & KKG doing the web-based screening and BS & SG formulating the selection criteria.

2.3 Study quality assessment

Quality of individual studies were assessed using the Cochrane collaboration tool using random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcomes assessment, incomplete outcome data, selective reporting and other bias as assessment attributes. Publication bias was assessed using funnel plots.

2.4 Statistical analysis

Analysis was conducted on a pooled population of 1480 patients identified with confirmed coronavirus infection from the five citations, using the comprehensive meta-analysis (CMA) software version 3, Biostat Inc., Englewood, NJ, USA. Heterogeneity was assessed using the Cochrane Q and Higgin's I² test and publication bias was assessed by funnel plots. [1-9] Depending on the presence or degree of heterogeneity (<45% low, 45–75% moderate and > 75% high) and the study characteristics, a fixed or random effect model to assess the effect size was selected. Where relative risk or odds ratio were not reported odds ratio was calculated from the reported events using Medcalc statistical software, © 2020 MedCalc Software Ltd, Ostend, Belgium.

3.0 Results:

This meta-analysis includes patients from five studies with confirmed SARS-CoV-2 infection, and compares the outcomes among 308 patients receiving ACEi/ARB with 1172 patients who did not receive ACEi/ARB. Bean et al analysed patients on ACEi and Liu et al ARB only, while the three other studies analysed the combination of ACEi & ARB. Hence we conducted this meta-analysis on the combined ACEi/ARB group.

The odds for risk of severity of disease was analysed from data extracted from all the five citations. The data from the study by Bean et al was included only for the analysis of the

effect of ACEi/ARB on the risk of severity of disease as the odds ratio for this outcome in patients on ACEi was clearly mentioned in their publication; we could not include their data on effect on death since this was nor reported separately as an outcome. (20). Similarly, data from the study of Liu et al (12) did not report on death separately. As such, the odds for death was analysed from the data extracted from the studies of Yang et al, Zeng et al, and Zhang et al (17,19, 21). The odds for risk for hospitalisation was analysed from the data extracted from the studies of Yang et al (19) and Zeng et al (17) only, since the other three studies did not report on this outcome.

In view of the numerous terminologies used to report various end points, we chose to assess the risk of severity of disease after extracting data from all five studies. The data on death in the three studies that reported it was homogeneous as was the data on risk for hospitalisation among the two studies with that information. The baseline characteristics of the studies compiled in table 1.

Study	Drug(n)	Non-	Age	Odds ratio of	Odds ratio of	Odds ratio of	Additional
		ACEi/ARB		Death	severity of	Hospitalisation	information
		(n)			disease		
Bean	ACEi (37)	168	63 ± 20	NA	OR 0-42 (CI	NA	NA
et al					0.14-1.00),		
20					p=0·058.		
Liu et	ACEi/ARB	34	65.2	NA	OR=0·21, 95%	NA	NA
al ¹⁸	(12)		(Mean)		CI: 0·05-0·85,		
					p=0·03.		

et al ¹⁹ (43) (Median) 0.067 to 1.511, 0.109 to 1.090, p=0.0699). 0.433 to 2.075, reduction in: p=0.0699). 1.CRP (11.5 to 1.002), p=0.0699). p=0.15) p=0.0699). p=0.89) 1.CRP (11.5 to 1.002), p=0.049, p=0.049. 119.2]; p=0.049. 2. Procalcitonin: 0.061 [0.044-0.131] vs 0.121 [0.052-0.295]; 0.121 [0.052-0.295]; 0.121 [0.052-0.008 0.295]; p=0.008 ACEI/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.78 to 1.812, in RT-PCR p=0.62). P=0.62). P=0.07) p=0.34). Pet (188) ACEI/ARB 940 64 OR 0.36 (CI OR 0.38 (CI OR 0.38), p=0.07) P=0.02) P=0.02) P=0.02) P=0.02) P=0.02	Yang	ACEi/ARB	83	66	OR 0.32 (CI	OR 0.35(CI	OR 0.95 (CI:	Significant
[4.0-58.2] vs 33.9 [5.1-119.2]; p=0.049. 2. Procalcitonin: 0.061 [0.044-0.131] vs 0.121 [0.052-0.295]; p=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.008 P=0.009 P=0	et al ¹⁹	(43)		(Median)	0.067 to 1.511,	0.109 to 1.090,	0.433 to 2.075,	reduction in:
See					p=0.15)	p=0.0699).	p=0.89)	1.CRP (11.5
Tight Tigh								[4.0-58.2] <i>vs</i>
P=0.049. P=0.061								33.9 [5.1-
Zeng ACEI/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al ¹⁷ (28) (Mean) 0.116 to 3.577, p=0.07) p=0.34). VALUE (Median) 0.16-0.80, 0.16-0.89,								119.2];
Procalcitonin: 0.061 [0.044- 0.131] vs								p=0.049.
Zeng ACEi/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al ¹⁷ (28) (Mean) 0.116 to 3.577, 0.939 to 6.449, 0.178 to 1.812, in RT-PCR p=0.62). p=0.07) p=0.34). Pet (188) 40 64 OR 0.36 (CI OR 0.38 (CI NA NA NA NA NA (Median) 0.16-0.80, 0.16-0.89,								2.
Zeng ACEi/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al ¹⁷ (28) (Mean) 0.116 to 3.577, p=0.07) p=0.34). The positivity Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA P et (188) (Median) 0.16-0.80, 0.16-0.89,								Procalcitonin:
Zeng ACEI/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al 17 (28) (Mean) (P=0.62). P=0.07) P=0.34). P et (188) (Median) O.16-0.80, O.16-0.89, O.16-0.89, O.16-0.89, O.16-0.89, O.16-0.89, O.16-0.89, O.16-0.89, O.121 [0.052-0.121 [0.052-0.295]; P=0.008 O.121 [0.052-0.295]; P=0.008 O.121 [0.052-0.295]; P=0.008 O.121 [0.052-0.295]; P=0.008 O.16-0.89, O.178 to 1.812, in RT-PCR P=0.07) P=0.34). O.178 to 1.812, in RT-PCR P=0.07) P=0.34). O.16-0.89, O.								0.061 [0.044-
Zeng ACEi/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al 17 (28) (Mean) D.116 to 3.577, D.939 to 6.449, D.178 to 1.812, in RT-PCR p=0.62). p=0.07) p=0.34). Pet (188) (Median) D.16-0.80, D.16-0.89, D.16-0.89, D.295]; p=0.008								0.131] <i>vs</i>
Zeng ACEi/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al 17 (28) (Mean) p=0.62). p=0.07) p=0.34). positivity Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA NA NA NA NA NA N								0.121 [0.052-
Zeng ACEi/ARB 47 60 OR 0.65 (CI OR 2.46 (CI OR 0.57 (CI No difference et al ¹⁷ (28) (Mean) 0.116 to 3.577, 0.939 to 6.449, p=0.62). p=0.07) p=0.34). positivity Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA Pet (188) (Median) 0.16-0.80, 0.16-0.89,								0.295];
et al ¹⁷ (28) (Mean) 0.116 to 3.577, 0.939 to 6.449, 0.178 to 1.812, in RT-PCR p=0.62). p=0.07) p=0.34). positivity Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA Pet (188) (Median) 0.16-0.80, 0.16-0.89,								p=0.008
et al ¹⁷ (28) (Mean) 0.116 to 3.577, 0.939 to 6.449, 0.178 to 1.812, in RT-PCR p=0.62). p=0.07) p=0.34). positivity Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA Pet (188) (Median) 0.16-0.80, 0.16-0.89,								
p=0.62). p=0.07) p=0.34). positivity	Zeng	ACEi/ARB	47	60	OR 0.65 (CI	OR 2.46 (CI	OR 0.57 (CI	No difference
Zhang ACEi/ARB 940 64 OR 0.36 (CI OR 0.38 (CI NA NA Pet (188) (Median) 0.16-0.80, 0.16-0.89,	et al ¹⁷	(28)		(Mean)	0.116 to 3.577,	0.939 to 6.449,	0.178 to 1.812,	in RT-PCR
P et (188) (Median) 0.16-0.80, 0.16-0.89,					p=0.62).	p=0.07)	p=0.34).	positivity
P et (188) (Median) 0.16-0.80, 0.16-0.89,								
P et (188) (Median) 0.16-0.80, 0.16-0.89,								
	Zhang	ACEi/ARB	940	64	OR 0.36 (CI	OR 0.38 (CI	NA	NA
$ a ^{21} $ $ p=0.01)$ $ p=0.02)$	Pet	(188)		(Median)	0.16-0.80,	0.16-0.89,		
	al ²¹				p=0.01)	p=0.02)		

Table 1: Baseline characteristics and individual odds ratio of the studies included for analysis. n=number of patients, CI= Confidence interval, OR= Odds Ratio, CRP= C-reactive protein, ACEi: Angiotensin converting enzyme inhibitor, ARB= Angiotensin receptor blocker.

3.1 Effect of use of ACEi/ARB in patients with COVID-19 on risk of severity of disease (Figure 2):

There was a statistically significant 44% reduction in the odds of risk of severity of disease in patients with COVID-19 on the ACEi/ARB group compared to those not on ACEi/ARB (OR: 0.56, 95% CI: $0.34-1.89, I^2=68.15$). There was a moderate degree of heterogeneity.




Figure 2: Forest plot comparing the effect of use of ACEi/ARB on risk of severity of disease in patients with COVID-19 with those not on ACEi/ARB. (SD)= severity of disease.

3.2 Effect of use of ACEI/ARB in patients with COVID-19 on death (Figure 3)

There was a statistically significant 62% (95% CI: 0.19-0.74, I²=0.000) reduction in the odds of death in the patients on ACEi/ARB when compared to those not on ACEi/ARB. There was negligible heterogeneity.

Study name		Statistics for	or each stud	ly		Odo	ls rati	o ar	nd 95°	<u>% C</u> I	
	Odds ratio	Lower limit	Upper limit	p-Value							
Yang et al (D)	0.320	0.067	1.528	0.153		+	-	+	- [1	
Zeng et al (D)	0.650	0.116	3.642	0.624	-	+		+	+	-	
Zhang et al (D)	0.360	0.162	0.800	0.012	.	+		-			
	0.384	0.199	0.741	0.004							
Heterogeneity: Q=0.	44, df=2, l ²	=0.000. P=0.8	30.		0.1	0.2	0.5	1	2	5	
3					Favo	ours A	ACEi/AF	RB F	avours	Contr	ol

5.5 Effect of use of ACEI/ AKB in patients with COVID-19 on nospitalisation:

There was a statistically non-significant 19% (95% CI: 0.42-1.55, I²: 0.000) reduction in odds of hospitalisation in the patients on ACEi/ARB compared to those not on ACEi/ARB. There was negligible heterogeneity. (Figure 5)

Study name		Statistics for	or each stud	Odds ratio and 95% CI			
	Odds ratio	Lower limit	Upper limit	p-Value			
Yang et al (H)	0.950	0.433	2.084	0.898			
Zeng et al (H)	0.570	0.178	1.825	0.344	 		
	0.810	0.422	1.553	0.525			
					0.1 0.2 0.5 1 2 5		
Heterogeneity: Q=	0.51, df=1,	12=0.000. P=0).47.				
4					Favours ACEi/ARB Favours Control		

4.0 Discussion:

Speculation over the deleterious effects of ACEi/ARB in patients with COVID-19 stems from the fact that SARS-CoV-2 uses the ACE2 receptor to enter target human cells (5). A few preclinical studies have suggested that RAAS inhibitors increase ACE2 expression, raising concerns regarding their safety in patients with COVID-19 (9). This thought was seemingly further strengthened by a retrospective study on hospitalised patients with COVID-19 in Wuhan, China, which reported that hypertensive patients on ACEi/ARB had an increased tendency to develop severe pneumonia with SARS COV 2 infection compared to those not on ACEi/ARB (54% vs. 32% respectively; p = 0.055) (17). This created confusion amongst patients and their health care workers since ACEi/ARB are an essential component of treatment not only in many individuals with hypertension but also in those with diabetes, coronary artery disease, heart failure and chronic kidney disease; sudden withdrawal of these medications in these patients might cause harm (22). However, findings from the same study showed that hypertensive patients with COVID-19 who were on ACEI/ARB had lesser hospitalisation (18% vs. 28%), lesser number of deaths (7% vs. 11%), and a higher number of discharges (75% vs. 61%) when compared to those not on ACEi/ARB; however, these observations failed to reach statistical significance due to the small number of patients analysed (17). In another study from China on elderly hypertensive patients with COVID-19, treatment with ARB was associated with a significant reduction in the risk of disease severity (OR=0.343, 95% CI 0.128-0.916, p=0.025) (18). A study by Yang et al. reported that compared to patients on non-ACEI/ARB antihypertensives, those on ACEI/ARB had a significant reduction in inflammatory markers, namely C-reactive protein (11.5 [ACEi/ARB] [4.0-58.2] vs. 33.9 [non ACEi/ARB] [5.1-119.2]; p=0.049) and procalcitonin (0.061 [ACEi/ARB] [0.044-0.131] vs. 0.121 [non ACEi/ARB] [0.052-0.295]; p=0.008), (19) consistent with previously described anti-inflammatory properties of ACEi/ARB (23, 24). This study also

revealed a much lower proportion of critical patients (9.3% vs. 22.9%; p=0.061), and a lower death rate (4.7% vs. 13.3%; p=0.216) in those receiving ACEi/ARB compared to those not on ACEi/ARB; however, these differences failed to reach statistical significance (19).

In a study from the United Kingdom, Bean et al. reported that in patients with COVID-19, those treated with ACEi had a lower rate of death or transfer to a critical care unit [OR 0.29 CI 0.10-0.75 p <0.01], after adjusting for age, gender, and comorbidities (hypertension, diabetes mellitus, ischaemic heart disease and heart failure) compared to those who were not on ACEi/ARB (20). Recently, Zhang et al. reported a large multicentre retrospective study on 1128 hospitalised hypertensive patients with COVID-19; there was a significant reduction in all-cause mortality (adjusted HR, 0.30; 95%CI, 0.12-0.70; P = 0.01) in patients treated with ACEi/ARB compared to those treated with other anti-hypertensive medications, even after adjusting for a large number of variables (21). This study also demonstrated that use of ACEi/ARB was associated with lower risk of septic shock when compared to those not on ACEi/ARB (adjusted HR, 0.36; 95% CI, 0.16-0.84; P = 0.01) (21).

The above noted five studies that have individually reported on the effect of ACEi/ARB in patients with COVID-19 are limited by the small number of patients studied and the varied outcomes reported, which makes it difficult to ascertain the effect of ACEi/ARB in patients with COVID-19. Ours is the first meta-analysis reporting on the effect of ACEi/ARB on death and severity of disease in patients with COVID-19. We report that patients with COVID-19 on ACEi/ARB had a statistically significant 44% reduction in the odds for risk of developing severe disease (OR: 0.56, (95% CI: 0.34-1.89, I²=68.15) p = 0.015) compared to those not on ACEi/ARB. The odds for hospitalisation are reduced by 19% (95% CI: 0.42-1.55, I²: 0.000)

among patients with COVID-19 on ACEI/ARB compared to those not on ACEI/ARB, which failed to reach statistical significance. Most importantly, our meta-analysis of the three studies that have reported on death, reveals a statistically significant 62% reduction (p=0.04) in the odds of death among patients with COVID-19 on ACEi/ARB compared to those not on ACEi/ARB, with negligible heterogeneity of data. The statistically significant benefits seen in our meta-analysis in the odds of developing severe disease and odds of death with use of ACEi/ARB in patients with COVID-19 strengthen the recommendations from European Societies of Cardiology (25), Heart Failure Society of America, American College of Cardiology, American Heart Association (26) and International Society of Hypertension (27) to continue ACEi/ARB in patients with COVID-19. The reduction in the odds of death and odds of risk of developing severe disease is not only reassuring concerning the safety of ACEi/ARB in patients with COVID-19 but also point towards the urgent need for an adequately powered RCT to confirm these benefits. Till such time, our meta-analysis adds to current knowledge confirming not only the safety of ACEi/ARB in patents with COVID-19 but also possible benefit in terms of reduction in death and risk of developing severe disease.

These findings are in keeping with the results of a meta-analysis of three studies with 70346 patients with non-COVID pneumonia, where use of ARB was associated with a significant reduction in the risk of pneumonia-related morbidity (OR=0.55, 95% CI; 0.43-0.70, p<0.01) and mortality (OR=0.55, 95% CI; 0.44-0.69, p<0.01) (18). In another retrospective study on 313 elderly patients, it was noted that the relative risk of developing a new pneumonia of mixed aetiology was higher in patients who were not on an ACEi when compared to those who were receiving ACE inhibitors [18% vs. 7%; RR 2.65 (95% CI 1.31–

5·35, p=0·007)] (28). It would appear that ACEi/ARB have a protective effect on pneumonia related pulmonary injury, which may be of benefit in patients with COVID-19 since the SARS-CoV-2 has a predilection for the lower respiratory tract.

Our meta-analysis has a few limitations. The five studies included for analysis used different primary and secondary end-points that led to a moderate degree of heterogeneity in the reported results; we circumvented this by restricting our meta-analysis to clinically relevant end-points of death, hospitalisation and severity of disease, which resulted in negligible heterogeneity in our analysis on hospitalisation and death. The number of patients in the individual studies were small and there were various confounders, which were partly addressed by pooling of the data from the individual studies. Last, but not the least, due to a very small number of patients in the studies that reported outcomes independently in patients with COVID-19 on an ACEi or ARB, we were unable to assess the independent effect of ACEi or ARB on death and severity of disease in patients with COVID-19.

The strength of our meta-analysis lies in the fact that in an evolving infectious disease pandemic with acute consequences, where generation of evidence at the earliest is crucial to guide management, the best way to increase the predictability of the question in focus is to perform pooled analysis, till results of a RCT becomes available. By pooling data from multiple small observational studies with multiple inherent confounding factors, and by performing a meta-analysis, we have largely circumvented the problems associated with the individual studies. This meta-analysis, highlighting the safety and possibly beneficial effects of ACEi/ARB, shall help physicians use ACEi/ARB in patients with COVID-19 till further information becomes available. Secondly, since, the parameters assessed and the outcomes

analysed varied enormously between the five studies, we analysed clinically relevant endpoints including death, risk of hospitalisation, and severity of illness.

5.0 Conclusion:

In conclusion, to our knowledge, this is the first meta-analysis on the effect of ACEi/ARB in patients with COVID-19 on clinically relevant end-points. We report that patients on ACEi/ARB, who develop COVID-19, do not have an adverse outcome; more importantly, within the limitations of a meta-analysis of retrospective observational studies, there was a statistically significant reduction in death, and severity of disease. The findings of this meta-analysis reinforce the recommendations issued by the various agencies to continue ACEi/ARB in patients with comorbidities who contract COVID-19.

References

- 1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-1242
- 2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* Published online March 13, 2020. doi:10.1001/jamainternmed.2020.0994

 3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10299):1054-1062.
- 4. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:343-346
- 5. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271-280.
- 6. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 274:33238–33243.
- 7. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277:14838–14843.

- 8. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor of SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203:631-637
- 9. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-2610.
- 10. Campbell DJ, Zeitz CJ, Esler MD et al. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE 2) in angiotensin peptide metabolism in human coronary circulation. J Hypertens 2004; 22:1971-1976.
- 11. Luque M, Martin P, Martell N, et al. Effects of captopril relate to increased levels of prostacyclin and angiotensin (1-7) in essential hypertension. J Hypertens 1996; 14:799-805.
- 12. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014; 4:7027.
- 13. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63:364-374.
- 14. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep 2016; 6:19840.
- 15. Kuba K, Imayi Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury. Nat Med 2005; 11:875-879.
- 16. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerated maladaptive left ventricular remodelling in response to myocardial infarction. Circ Heart Fail 2009; 2:446-455.


- 17. Zeng Z, Sha T, Zhang Y et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20054825
- 18. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020.03.20.20039586; doi: https://doi.org/10.1101/2020.03.20.20039586.
- 19. Yang G, Tan Z, Lou Z et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-Patients With Hypertension. . medRxiv preprint doi:

https://doi.org/10.1101/2020.03.31.20038935

- 20. Bean D, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-sile UK acute Hospital Trust. medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788
- 21. Zhang P, Zhu L, Cai J et al. Association of Inpatient Use of Angiotensin Converting
 Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With
 Hypertension Hospitalized With COVID-19. Circ Res. DOI: 10.1161/CIRCRESAHA.120.317134

 22. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart
 failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot,
 randomised trial. Lancet 2019; 393: 61-73.
- 23. Montecucco F, Pende A, Mach F. The Renin-Angiotensin System Modulates
 Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical
 Studies. Mediators of Inflammation 2009, doi:10.1155/2009/752406

- 24. Dandona P, Dhindsa S, Ghanim H. *et al.* Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. *J Hum Hypertens* 21, 20–27 (2007). https://doi.org/10.1038/sj.jhh.1002101
- 25. European Societies of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. March 13, 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on hyper tension-on-ace-inhibitors-and-ang.
- 26. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. March 17, 2020. Available at: https://www.acc. org/latest-in-cardiology/ artic les/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
- 27. A statement from the International Society of Hypertension on COVID-19. March 16,2020. Available at: https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/
- 28. Sekizawa K, Matsui T, Nakagawa T. ACE inhibitors and Pneumonia. Lancet 1998, 352: 1069



Study name		Statistics to	r each stud	У		Odds ra	itio and	95% C	ı
	Odds ratio	Lower limit	Upper limit	p-Value					
Yang et al (SD)	0.350	0.109	1.124	0.078			■┤		
Zeng et al (SD)	2.460	0.939	6.445	0.067			+	\vdash	
Liu et al (SD)	0.210	0.050	0.882	0.033		-			
Bean et al (SD)	0.420	0.140	1.260	0.122			■+		
Zhang (SD)	0.380	0.163	0.886	0.025		-			
	0.559	0.349	0.895	0.015			•		
Heterogeneity: Q=12	2.56, df=4,	I ² =68.15. P=0	.01.		0.01	0.1	1	10	100

Odds ratio and 95% CI

Favours ACEi/ARB Favours Control

Statistics for each study

Study name

Study name		Statistics to	or each stud	<u>ıy</u>	Odds ratio and 95% Ci
	Odds ratio	Lower limit	Upper limit	p-Value	
Yang et al (D)	0.320	0.067	1.528	0.153	
Zeng et al (D)	0.650	0.116	3.642	0.624	- - -
Zhang et al (D)	0.360	0.162	0.800	0.012	│ │ ■
	0.384	0.199	0.741	0.004	

Otatiatian famorale atualis

Heterogeneity: Q=0.44, df=2, I²=0.000. P=0.80.

C4-----

0.1 0.2 0.5 1 2 5

Odds watte and OFO/ OI

	Odds ratio	Lower limit	Upper limit	p-Value
Yang et al (H)	0.950	0.433	2.084	0.898
Zeng et al (H)	0.570	0.178	1.825	0.344
	0.810	0.422	1.553	0.525

Odds ratio and 95% CI

Favours ACEI/ARB Favours Control

0.1 0.2 0.5 1 2

Statistics for each study

Study name

Heterogeneity: Q=0.51, df=1, I2=0.000. P=0.47.

Study	Drug(n)	Non- ACEi/ARB (n)	Age	Odds ratio of Death	Odds ratio of severity of disease	Odds ratio of Hospitalisation	Additional information
Bean et al ²⁰	ACEi (37)	168	63 ± 20	NA	OR 0.42 (CI 0.14-1.00), p=0.058.	NA	NA
Liu et al ¹⁸	ACEi/ARB (12)	34	65.2 (Mean)	NA	OR=0·21, 95% CI: 0·05-0·85, p=0·03.	NA	NA
Yang et al ¹⁹	ACEi/ARB (43)	83	66 (Median)	OR 0.32 (CI 0.067 to 1.511, p=0.15)	OR 0.35(CI 0.109 to 1.090, p=0.0699).	OR 0.95 (CI: 0.433 to 2.075, p=0.89)	Significant reduction in: 1.CRP (11.5 [4.0-58.2] vs 33.9 [5.1-119.2]; p=0.049. 2. Procalcitonin: 0.061 [0.044-0.131] vs 0.121 [0.052-0.295]; p=0.008
Zeng et al ¹⁷	ACEi/ARB (28)	47	60 (Mean)	OR 0.65 (CI 0.116 to 3.577, p=0.62).	OR 2.46 (CI 0.939 to 6.449, p=0.07)	OR 0.57 (CI 0.178 to 1.812, p=0.34).	No difference in RT-PCR positivity
Zhang P et al ²¹	ACEi/ARB (188)	940	64 (Median)	OR 0.36 (CI 0.16-0.80, p=0.01)	OR 0.38 (CI 0.16-0.89, p=0.02)	NA	NA